cygnus
GLP-1 Apprentice
If you'd like to save a click, this is their injectable GLP-1 drug. It looks like results were 12.3% loss through 28 weeks, which admittedly is not terribly exciting. Competition breeds innovation though, so keep 'em coming.
finance.yahoo.com
Pfizer (PFE) Announces Positive Phase 2b Results for Obesity Drug Showing 12.30% Weight Loss
Pfizer Inc. (NYSE:PFE) is one of the best large cap stocks to buy under $50. On February 3, Pfizer announced positive topline results from its Phase 2b VESPER-3 study of PF-08653944 (MET-097i), which is an injectable GLP-1 receptor agonist. The trial met its primary endpoint and showed a...